Bayer HealthCare
Pharmaceuticals
-
Wednesday - May 16, 2012
Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session » more
-
Wednesday - May 9, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome » more
-
Wednesday - May 2, 2012
Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) » more
-
Tuesday - April 24, 2012
Not intended for U.S. and UK media
Bayer expands targeted cancer therapy collaboration with Amgen » more
-
Tuesday - April 17, 2012
Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
Outcomes from XAMOS study of more than 17,000 orthopaedic surgery patients provide further confirmation of clinical value of rivaroxaban / XAMOS reaffirms robust findings from RECORD – the world’s largest trial programme assessing oral anticoagulation in people requiring hip or knee replacement / Rivaroxaban is the world’s most prescribed new oral anticoagulant in the orthopaedic setting, with almost 2 million patients treated in this indication alone » more
-
Sunday - April 15, 2012
Not intended for U.S. and UK media - Molecular Imaging:
Bayer sells PET tracers to Piramal » more
-
Thursday - April 12, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE » more
-
Wednesday - April 11, 2012
Not intended for U.S. and UK media
Bayer Updates U.S. Labels for Drospirenone-containing Combined Oral Contraceptives » more
-
Tuesday - April 3, 2012
Not intended for U.S. and U.K. Media
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival » more
-
Wednesday - March 28, 2012
Not intended for U.S. and UK Media - 103rd Annual Meeting American Association for Cancer Research:
Bayer to Present New Data on Oncology Pipeline
New Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development Portfolio » more
-
Tuesday - March 27, 2012
Bayer HealthCare and Beijing’s Tsinghua University extend innovative drug discovery partnership » more
-
Monday - March 26, 2012
Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine » more
-
Monday - March 19, 2012
Not intended for UK and US Media: Treatment of Pulmonary Embolism (PE):
Results of the Phase III EINSTEIN-PE Study with Bayer’s Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012 » more
-
Thursday - March 15, 2012
Not intended for U.S. and UK Media
U.S. FDA approves Natazia™ as the first combined oral contraceptive to treat heavy menstrual bleeding (HMB) » more
-
Thursday - March 8, 2012
Not intended for U.S. and UK Media
EYLEA® (aflibercept) Injection approved for the Treatment of Wet Age-Related Macular Degeneration in Australia
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials » more
-
Thursday - March 1, 2012
Not intended for UK Media
Bayer HealthCare integrates its Contrast Media, Injector and Interventional businesses
New business unit named “Radiology and Interventional” broadens customer offerings and speeds up innovations / Unit encompasses leading brands Gadovist®, Ultravist®, AngioJet Ultra®, Mark 7 Arterion™ Injection System and Stellant® D CT Injection System » more
-
Tuesday - February 28, 2012
Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Granted Priority Review by US FDA to Prevent Secondary Cardiovascular Events in Patients with ACS » more
-
Monday - February 20, 2012
Not intended for U.S. and UK Media
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye » more
-
Friday - January 27, 2012
Not intended for U.S. and UK media - Indication extension for contrast medium
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older » more
-
Wednesday - January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation » more
Copyright @ Bayer AG
Search
Links
Publications
Newsletter
Events
Download Center - Selection
